earnings
confidence high
sentiment neutral
materiality 0.70
COMPASS Pathways H1 2023 net loss $52.5M; Phase 3 psilocybin trials on track
COMPASS Pathways plc
2023-Q2 EPS reported
-$1.19
- Net loss for H1 2023: $52.5M ($1.19 loss per share) vs $42.2M ($1.00) in H1 2022.
- Cash $148.2M; secured $50M term loan from Hercules Capital, $28.1M drawn.
- COMP360 Phase 3 TRD trials on track; topline data expected summer 2024 (COMP 005) and mid-2025 (COMP 006).
- AMA accepted CPT III code for in-person psychedelic therapy support, aligning with COMP360 requirements.
- ATAI exercised demand registration rights for 7,935,663 shares; filing required within 45 days.